Company Lead Compound Initial
Preclinical Phase 1 Phase 2 Phase 3
Strategic Investment
COMP360 /
Psilocybin therapy 1,2
Treatment Resistant Depression
Our Programs
PCN-101 /
Treatment Resistant Depression
RL-007 /
Compound 3
Cognitive Impairment Associated with Schizophrenia
DMX-1002 /
Opioid Use Disorder
GRX-917 /
Generalized Anxiety Disorder
NN-101 /
Mild Traumatic Brain Injury
VLS-01 /
Treatment Resistant Depression
EMP-01 /
MDMA derivative
Post Traumatic Stress Disorder
RLS-01 /
Salvinorin A
Treatment Resistant Depression
KUR-101 /
Deuterated Mitragynine
Opioid Use Disorder
Opioid Use Disorder

Our Compounds


Hallucinogenic plants have been part of the human experience for thousands of years, with users aware of their potential for healing, transformation, and growth – as well as their dangers – since as far back as prehistory. Now that public attention has been captured by these extraordinary plants, it is more important than ever to understand the history, pharmacology, and therapeutic potential of psilocybin and other psychedelics.

accordion image LEARN MORE

Arketamine and esketamine are the R(-) and S(+) enantiomers of ketamine, a compound that has been used for everything from anaesthesia and sedation to chronic pain and depression. Recently, esketamine as a nasal spray (Spravato™) made history as the first psychedelic-type substance approved by the U.S Food and Drug Administration (FDA) for treatment resistant depression.

accordion image LEARN MORE
Ibogaine & Noribogaine

Between 1991 and 2011, against the backdrop of a PR campaign aimed at convincing consumers that opioids were both safe and non-addictive , the United States saw a threefold spike in annual opioid prescription rates (from 76 to 219 million). Before long, misuse and addiction had exploded: By 2018, a full 2.1 million Americans met the diagnostic criteria for opioid use disorder, while 2 million misused prescription opioids for the first time. 47,600 people died from an opioid overdose.

accordion image LEARN MORE

While psychedelics are an important component of the dawning mental healthcare revolution, it is critical to recognize that a comprehensive response to the global mental health crisis ought to be as diverse as possible. To this end, GABA Therapeutics is pursuing a natural approach based on the brain’s ability to correct imbalances that underlie many CNS disorders.

accordion image LEARN MORE

While psychedelics are an important component of the dawning mental healthcare revolution, non-psychedelics will also play key roles in both treatment and prevention of new cases. To this end, Neuronasal, Inc. is developing well-known and FDA-approved OTC compound N acetylcysteine (NAC) as a promising treatment for mild traumatic brain injury (mTBI) using intranasal administration for direct nose-to-brain delivery.

accordion image LEARN MORE
N, N-dimethyltryptamine

Even among psychedelics, DMT is extraordinary. Sometimes called the “sprit molecule”, this endogenous psychoactive compound occurs naturally in many plants and animals, and has been implicated in everything from dreaming to religious experiences. However, unlike most psychedelics, for example psilocybin, DMT exhibits extremely rapid onset and short duration of action.

accordion image LEARN MORE
MDMA derivative

Commonly known as ‘ecstasy’, one compound is seeing a resurgence not on the dancefloors, but rather in the clinics of researchers who have identified its value in treating a number of psychiatric disorders. With a Phase III trial now underway, many anticipate MDMA to be the first psychedelic-like drug to be approved by the FDA for the treatment of PTSD.

accordion image LEARN MORE

Despite limited scientific information, the DEA announced their intention to classify kratom, Mitragynine and 7-hydroxymitragynine as Schedule I on the Controlled Substance Act in 2016. Shortly after, a major push-back consisting of 23,000 written pleas from the general public, legislators and scientific community members challenged the DEA’s decision. For the first time in history, the DEA withdrew their intention to schedule a substance.

accordion image LEARN MORE

Our Technologies


Introspect believes that high-quality digital combination therapies will increase the safety and effectiveness of many mental health drugs. Digital therapeutics (DTx) will provide personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.

accordion image LEARN MORE

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles…

accordion image LEARN MORE

Receive the latest news on atai and innovations in the space.